Antibe Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ATBPF research report →
Price Chart
About the company
Antibe Therapeutics Inc. is a biotechnology company focused on the innovation and development of novel therapeutic solutions and medical devices. The firm operates across Canada, Europe, the United States, and other international markets, concentrating its efforts on pain management, inflammation, and regenerative medicine.
- CEO
- Daniel Marcel Legault
- IPO
- 2014
- Employees
- 11
- HQ
- Toronto, ON, CA
Get TickerSpark's AI analysis on ATBPF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $11.43M
- P/E
- -0.80
- PEG
- -0.05
- P/S
- 0.00
- P/B
- 0.38
- EV/EBITDA
- -0.46
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -40.16%
- ROIC
- -28.48%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-20,546,000
- Net Income
- $-19,475,000+22.3%
- EPS
- $-0.37+24.5%
- OCF Growth
- +3.6%
- FCF Growth
- +3.6%
- 52W High
- $0.22
- 52W Low
- $0.19
- 50D MA
- $0.22
- 200D MA
- $0.22
- Beta
- 0.58
- RSI (14)
- 0
- Avg Volume
- 9.61K
No earnings-call transcripts are available for ATBPF yet.
- Free Float
- 95.9%
- Shares Outstanding
- 53.01M
- Float Shares
- 50.85M
Our ATBPF coverage
Recent articles, reports, and earnings notes.
No research on ATBPF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ATBPF report →Analyzing Evelo Biosciences (NASDAQ:EVLO) & Antibe Therapeutics (OTCMKTS:ATBPD)
defenseworld.net · Oct 31
Antibe Announces Appointment of Receiver
businesswire.com · Apr 24
Antibe Provides Update on CCAA Proceedings
businesswire.com · Apr 19
Antibe Announces Granting of Initial Order Under Companies' Creditors Arrangement Act
businesswire.com · Apr 9
Antibe to File an Application for an Initial Order Under Companies' Creditors Arrangement Act
businesswire.com · Apr 9
Antibe to Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine Meeting
businesswire.com · Mar 7
Antibe Announces Unfavorable Decision in Arbitration With Nuance Pharma
businesswire.com · Mar 4
Antibe Reports Q3 2024 Interim Financial and Operating Results
businesswire.com · Feb 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.